COVID-19 remains an ongoing and unprecedented public health challenge, affecting millions of people worldwide and placing huge demands on healthcare systems. Join us for a promotional webinar providing an updated understanding of the COVID-19 landscape. It covers current global trends, contextualizes vaccines used early in the pandemic, and introduces Novavax’s recombinant protein vaccine. Our expert panel speaks to the vaccine’s attributes, highlighting key differentiating factors including efficacy and immunogenicity data, within the current prevention paradigm. Drawing on experiences from the previous winter season, this educational activity is an excellent opportunity to acquire knowledge and insights for the continuing efforts to advise, prevent, and protect in autumn/winter 2023.
This was a promotional event initiated, organised and funded by Novavax.
The Nuvaxovid™ ▼ COVID-19 Vaccine (recombinant, adjuvanted)—also known as NVX-CoV2373—has been granted conditional marketing authorisation in the European Union for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The vaccine should be used in accordance with official recommendations.
Please refer to your local product insert for more information.
Global information for healthcare professionals is available at: https://www.novavaxcovidvaccine.com
Suspected Adverse Events should be reported via the national reporting system which can be accessed at: https://www.novavaxcovidvaccine.com/
COM-AU-NVD-2300002 | September 2023
Medscape © 2023 WebMD Medical Affairs Services, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
This promotional webinar was initiated, organised and funded by Novavax. This presentation reflects the professional experience and opinion of the presenter. Treatment-related statements do not necessarily reflect Novavax's position nor are they necessarily in line with authorised use in all countries.
Please refer to your local product insert for more information.
Cite this: Jörg Schelling MD, Catherine Cosgrove MBBS MRCP PhD DipHIV. Leveraging a Novel Protein Vaccine to Widen Reach and Close the Vaccination Gap - Medscape - Sep 29, 2023.
